Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
Healthcare
$16.03 +1.97%
+$0.38 today
- Market cap
- $3.00B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
52W Low $8.06High $25.00
Volume 2.44M
Average 1.71M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$468.18M
FY 2025 · Annual
Net Income
-$446.21M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.46M | 2.24M | 2.05M |
| Gross Profit | 0 | 0 | (2.46M) | (2.24M) | (2.05M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
| Selling, General & Admin | 28.72M | 28.2M | 31.4M | 62.48M | 69.85M |
| Operating Expenses | 150.03M | 170.96M | 239.7M | 341.64M | 466.14M |
| Depreciation & Amortization | 1.09M | 1.68M | 1.67M | 1.67M | 2.05M |
| EBITDA | (148.2M) | (163.5M) | (234.26M) | (315.75M) | (437.97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (150.03M) | (170.96M) | (242.16M) | (343.89M) | (468.18M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 742K | 2.92M | 7.64M | 26.92M | 29.86M |
| Interest Expense | 0 | 2.92M | 0 | 0 | 6.19M |
| Other Income / Expenses | 734K | 2.86M | 6.23M | 26.47M | 21.97M |
| Income Before Tax | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| EPS (Diluted) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| 50.9M | 51.98M | 59.68M | 94.14M | 128.44M | |
| 50.9M | 51.98M | 59.68M | 94.14M | 128.44M |
DYN Earnings Waterfall · TTM
NASDAQ:DYN · Revenue to Net Income
Key Ratios
EPS$-3.33
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$519.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.33, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 8-K | Current report | Sep 29, 2026 |
How much revenue does DYN generate?
Dyne Therapeutics, Inc. (DYN) reported $0.00 of revenue in fiscal 2025.
Is DYN profitable?
Dyne Therapeutics, Inc. (DYN) reported -$446.21M of net income.
Continue the stock analysis
Jump to another research area for this company.